Get the Stockscreener App
0.61
2.37%
-0.0148
After Hours:
.60
-0.01
-1.64%
Icecure Medical Ltd stock is traded at $0.61, with a volume of 174.49K.
It is down -2.37% in the last 24 hours and down -4.94% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$0.6248
Open:
$0.6144
24h Volume:
174.49K
Relative Volume:
0.32
Market Cap:
$30.26M
Revenue:
$2.91M
Net Income/Loss:
$-15.61M
P/E Ratio:
-1.5885
EPS:
-0.384
Net Cash Flow:
$-14.50M
1W Performance:
-4.37%
1M Performance:
-4.94%
6M Performance:
-49.17%
1Y Performance:
+12.92%
1-Day Range:
$0.61
$0.62
1-Week Range:
$0.60
$0.6445
52-Week Range:
$0.5461
$1.57
Icecure Medical Ltd Stock (ICCM) Company Profile
Icecure Medical Ltd Stock (ICCM) Latest News
IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com Australia
Ex-ad industry employees launch a new digital agency 'itch' - afaqs!
IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com Canada
IceCure reports high success rate in breast cancer trial - Investing.com India
Why Is Interactive Strength Stock Surging Today? - Benzinga
IceCure reports high success rate in breast cancer trial - Investing.com
InCred's Aditya Sood Reveals Key Factors Behind Selecting Indraprastha Medical From Hospital Sector - Business Today
IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com UK
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96 - StreetInsider.com
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PR Newswire
The time has not yet come to remove your chips from the table: Icecure Medical Ltd (ICCM) - SETE News
What will the future hold for Icecure Medical Ltd (NASDAQ:ICCM) stock? - US Post News
FDA AdComm to discuss IceCure's ProSense on Nov. 7 - MSN
Study: Liquid Nitrogen-Based Cryoablation Safe for Treating Treating Tumors of the Lung, Bone and Soft Tissues - Imaging Technology News
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues - StockTitan
H.C. Wainwright maintains Buy rating on IceCure Medical stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy rating on IceCure Medical stock - Investing.com India
Icecure Medical Ltd (ICCM) deserves closer scrutiny - US Post News
H.C. Wainwright maintains Buy rating on IceCure Medical stock - Investing.com
IceCure seeks FDA nod for breast cancer treatment - Investing.com
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 - PR Newswire
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 - StockTitan
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences - PR Newswire
Icecure Medical Ltd (ICCM) can make a big difference with a little luck - SETE News
Icecure Medical Ltd (ICCM) produces promising results - US Post News
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Malaysian Reserve
IceCure expands patent portfolio with USPTO allowance - Investing.com
IceCure Medical Strengthens Patent Portfolio - TipRanks
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - PR Newswire
IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com India
IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com Canada
IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com
IceCure Medical stock target cut, retains buy rating on Q2 results By Investing.com - Investing.com South Africa
IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com Australia
IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com UK
IceCure Medical Ltd (NASDAQ:ICCM) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: IceCure Medical reports growth and upcoming FDA panel - Investing.com India
Earnings call: IceCure Medical reports growth and upcoming FDA panel By Investing.com - Investing.com Australia
Earnings call: IceCure Medical reports growth and upcoming FDA panel By Investing.com - Investing.com Canada
Earnings call: IceCure Medical reports growth and upcoming FDA panel - Investing.com
Earnings call: IceCure Medical reports growth and upcoming FDA panel By Investing.com - Investing.com UK
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates - MSN
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Malaysian Reserve
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - PR Newswire
ICCM (Icecure Medical) Days Inventory : 422.18 (As of Mar. 2024) - GuruFocus.com
IceCure Medical (ICCM) Set to Announce Earnings on Tuesday - Defense World
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 - Longview News-Journal
IceCure Medical Takes Next Major Initiative as it Prepares to Ac - GuruFocus.com
Icecure's Prosense destroys 100% of breast cancer tumors - BioWorld Online
Taking the lead: Icecure Medical Ltd (ICCM) - SETE News
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):